Skip to main content

Odactra FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 28, 2025.

FDA Approved: Yes (First approved March 1, 2017)
Brand name: Odactra
Generic name: house dust mite allergen extract
Dosage form: Sublingual Tablets
Company: ALK-Abelló A/S
Treatment for: House Dust Mite Allergies

Odactra (house dust mite allergen extract) is a sublingual allergy immunotherapy (SLIT) tablet indicated as immunotherapy for house dust mite (HDM) allergies.

Development timeline for Odactra

DateArticle
Feb 28, 2025Approval FDA Approves Odactra for the Treatment of House Dust Mite Allergy in Young Children
Jan 25, 2023Approval U.S. FDA Approves ALK's Odactra (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents
Mar  1, 2017Approval FDA Approves Odactra for House Dust Mite Allergies
Apr 12, 2016Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.